{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:52:09Z","timestamp":1793404329070,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"am","delay-in-days":298,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.annder.2024.103264","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:37:43Z","timestamp":1711427863000},"page":"103264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients"],"prefix":"10.1016","volume":"151","author":[{"given":"A.","family":"Louchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"El Aarbaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jelti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Belmondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103264_b0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jid.2018.07.042","article-title":"Incidence and mortality of pemphigus in France","volume":"139","author":"Jelti","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0010","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2024.103264_b0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.annder.2024.103264_b0020","first-page":"927","article-title":"Autoimmune bullous skin diseases. Part 2: diagnosis and therapy","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2024.103264_b0025","first-page":"844","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2024.103264_b0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2024.103264_b0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0040","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Pemphigus Nat Rev Dis Primer"},{"key":"10.1016\/j.annder.2024.103264_b0045","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.annder.2024.103264_b0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.annder.2024.103264_b0055","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2024.103264_b0070","doi-asserted-by":"crossref","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA Testing of Anti-Desmoglein 1 and 3 Antibodies in the Management of Pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0080","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103264_b0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.annder.2019.01.018","article-title":"Update of the French recommendations for the management of pemphigus","volume":"146","author":"Jelti","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103264_b0090","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0095","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2021.10.034","article-title":"Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: a nationwide study","volume":"86","author":"Joly","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2024.103264_b0120","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jaad.2020.06.024","article-title":"The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: daily practice data from a retrospective study","volume":"83","author":"Rashid","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103264_b0125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamadermatol.2017.5176","article-title":"Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus","volume":"154","author":"Sanchez","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:47:05Z","timestamp":1711428425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0151963824000206"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103264","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103264"}}